An update to "The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe"

Mark Jit; Marie-Josée J Mangen; Hugues Melliez; Yazdan Yazdanpanah; Joke Bilcke; Heini Salo; W John Edmunds; Philippe Beutels

doi:10.1016/j.vaccine.2010.08.060

An update to "The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe"

Vaccine. 2010 Nov 3;28(47):7457-9. doi: 10.1016/j.vaccine.2010.08.060. Epub 2010 Sep 21.

Authors

Mark Jit, Marie-Josée J Mangen, Hugues Melliez, Yazdan Yazdanpanah, Joke Bilcke, Heini Salo, W John Edmunds, Philippe Beutels

PMID: 20846529
DOI: 10.1016/j.vaccine.2010.08.060

Abstract

A cost-effectiveness analysis of rotavirus vaccination in Belgium, England and Wales, Finland, France and the Netherlands published in 2009 was updated based on recent studies on rotavirus burden of disease and vaccine efficacy. All the qualitative conclusions in the previous study were found to remain valid. Vaccination remains cost-effective in Finland only when using plausible tender prices.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cost of Illness
Cost-Benefit Analysis
Europe / epidemiology
Gastroenteritis / economics
Gastroenteritis / epidemiology
Gastroenteritis / prevention & control
Gastroenteritis / virology
Humans
Models, Economic
Rotavirus Infections / economics
Rotavirus Infections / epidemiology
Rotavirus Infections / prevention & control*
Rotavirus Vaccines / economics*
Vaccination / economics*

Substances

Rotavirus Vaccines